About N-acyl-aromatic-L-amino acid amidohydrolase (carboxylate-forming)
N-acyl-aromatic-L-amino acid amidohydrolase (carboxylate-forming) (ACY3) is a protein
from Homo sapiens identified by UniProt accession
Q96HD9, 319 residues long.
MolForge cross-references it against 0 known binders and
55 disease associations.
Target properties
| Protein name | N-acyl-aromatic-L-amino acid amidohydrolase (carboxylate-forming) |
| UniProt accession | Q96HD9 |
| Gene | ACY3 |
| Organism | Homo sapiens |
| Length | 319 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (55)
Diseases linked to this target (Open Targets).
- serum metabolite measurement · score 0.43
- neurodegenerative disease · score 0.38
- urinary metabolite measurement · score 0.37
- lysosomal storage disease · score 0.34
- Alzheimer disease · score 0.34
- multiple sclerosis · score 0.34
- Parkinson disease · score 0.34
- glioblastoma multiforme · score 0.13
- Barrett's esophagus · score 0.07
- hemoglobin E-beta-thalassemia syndrome · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96HD9-F1 | alphafold | PREDICTED | 95.29 | — |
Amino-acid sequence (319 residues)
MCSLPVPREP LRRVAVTGGT HGNEMSGVYL ARHWLHAPAE LQRASFSAVP VLANPAATSG CRRYVDHDLN RTFTSSFLNS RPTPDDPYEV TRARELNQLL GPKASGQAFD FVLDLHNTTA NMGTCLIAKS SHEVFAMHLC RHLQLQYPEL SCQVFLYQRS GEESYNLDSV AKNGLGLELG PQPQGVLRAD IFSRMRTLVA TVLDFIELFN QGTAFPAFEM EAYRPVGVVD FPRTEAGHLA GTVHPQLQDR DFQPLQPGAP IFQMFSGEDL LYEGESTVYP VFINEAAYYE KGVAFVQTEK FTFTVPAMPA LTPAPSPAS
Explore N-acyl-aromatic-L-amino acid amidohydrolase (carboxylate-forming) with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets